Corium International Inc (CORI) Given Average Rating of “Buy” by Analysts

Shares of Corium International Inc (NASDAQ:CORI) have earned an average rating of “Buy” from the nine brokerages that are covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $13.00.

A number of analysts recently issued reports on CORI shares. Jefferies Group set a $10.00 target price on shares of Corium International and gave the stock a “buy” rating in a research report on Sunday, October 29th. HC Wainwright set a $15.00 target price on Corium International and gave the company a “buy” rating in a research note on Friday, November 17th. Needham & Company LLC raised their price objective on Corium International from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, November 20th. Zacks Investment Research upgraded Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, November 28th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $14.00 price objective on shares of Corium International in a research note on Friday, December 22nd.

Corium International (NASDAQ:CORI) traded up $0.58 on Tuesday, reaching $13.02. 250,338 shares of the company were exchanged, compared to its average volume of 195,466. The firm has a market cap of $449.38, a P/E ratio of -8.24 and a beta of 1.59. Corium International has a 12-month low of $3.44 and a 12-month high of $13.93. The company has a debt-to-equity ratio of 5.91, a quick ratio of 1.34 and a current ratio of 1.40.

Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.06. The firm had revenue of $9.32 million during the quarter, compared to the consensus estimate of $7.48 million. Corium International had a negative net margin of 148.07% and a negative return on equity of 403.15%. analysts expect that Corium International will post -1.43 EPS for the current year.

In related news, major shareholder Life Sciences Maste Perceptive purchased 510,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 18th. The stock was acquired at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Perceptive Advisors Llc purchased 50,350 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The stock was bought at an average price of $11.83 per share, with a total value of $595,640.50. The disclosure for this purchase can be found here. 30.80% of the stock is currently owned by company insiders.

Several large investors have recently added to or reduced their stakes in CORI. Bank of New York Mellon Corp boosted its position in shares of Corium International by 161.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock valued at $494,000 after purchasing an additional 40,891 shares during the period. Teachers Advisors LLC acquired a new stake in Corium International during the 2nd quarter worth about $272,000. TIAA CREF Investment Management LLC acquired a new stake in Corium International during the 2nd quarter worth about $411,000. New York State Common Retirement Fund acquired a new stake in Corium International during the 2nd quarter worth about $158,000. Finally, State Street Corp acquired a new stake in Corium International during the 2nd quarter worth about $1,840,000. Institutional investors and hedge funds own 87.29% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2018/02/20/corium-international-inc-cori-given-average-rating-of-buy-by-analysts.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply